Aptose to Present at Upcoming Investor Conferences
Aptose Biosciences, a clinical-stage biotechnology firm, announced its participation in two upcoming investor conferences. The RBC Capital Markets Global Healthcare Virtual Conference is set for May 19, 2021, from 11:30 AM to 11:55 AM EDT, featuring a fireside chat with Gregory J. Renza, M.D. The Jefferies Virtual Healthcare Conference follows on June 2, 2021, at 2:00 PM EDT, where Aptose will present a slide deck and host a webcast. The company focuses on developing innovative cancer therapeutics, including luxeptinib and APTO-253, aimed at treating various hematological malignancies.
- None.
- None.
SAN DIEGO and TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in upcoming investor conferences:
2021 RBC Capital Markets Global Healthcare Virtual Conference
| Date: | Wednesday, May 19, 2021 | |
| Time: | 11:30 AM – 11:55 AM EDT | |
| Format: | Fireside Chat moderated by Gregory J. Renza, M.D., Equity Research – Biotechnology | |
| Conference Information: Link | ||
Jefferies Virtual Healthcare Conference
| Date: | Wednesday, June 2, 2021 | |
| Time: | 2:00 PM – 2:25 PM EDT | |
| Format: | Aptose Slide Presentation and Webcast | |
| Conference Information: Link | ||
The Aptose management team also will be hosting 1x1 meetings during the events.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies. The first investigational product, luxeptinib, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML). The second investigational product, APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).
For further information, please contact:
| Aptose Biosciences Inc. Susan Pietropaolo Investor Relations 201-923-2049 spietropaolo@aptose.com | LifeSci Advisors, LLC Dan Ferry, Managing Director 617-535-7746 Daniel@LifeSciAdvisors.com | |
FAQ
What are the dates for Aptose's investor conferences in 2021?
What time will Aptose present at the RBC Capital Markets Conference?
How can I access the Jefferies Virtual Healthcare Conference presentation by Aptose?
What is the focus of Aptose Biosciences' research?
What are the investigational products highlighted in the press release for Aptose?
